Biochemist receives STAC grant to find treatment for C. albicans infection in premature infants

A $200,000 grant from the Rhode Island Science and Technology Advisory Council (STAC) is helping a Bryant University biochemist find a treatment for a fungal infection that is often lethal to premature infants.

The funding - the first ever received by Bryant from STAC - supports a research collaboration between Christopher Reid, assistant professor in Bryant's Department of Science and Technology, and Joseph Bliss, M.D., of Brown University and Women & Infants Hospital.

Together, they are taking aim at Candida albicans, a common fungus that can cause a systemic infection fatal to 60 percent of premature infants who contract it. Their research hopes to identify antigens that could be used as a target for a therapeutic antibody, which ultimately could help a premature infant's underdeveloped immune system combat a C. albicans infection.

The grant enables Reid to equip the University's 10,000-square-foot laboratory for research he and his undergraduate students are conducting in glycolipidomics and proteomics - "areas that are exploding in biology," Reid said.

Reid works closely with his undergraduates to provide hands-on training and experience in the isolation and characterization of biomolecules. For example, students in his organic chemistry course are troubleshooting one component of the C. albicans research. In his Foundations in Pharmaceutical Science class, his students built a virtual biotech company. In groups, they selected a disease, decided how they were going to generate a product, and simulated the process of securing financing for their startup businesses.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Research identifies antigen-specific peripheral T follicular helper cells in COVID-19 infected patients